MCL1 and osteosarcoma: Previous studies have shown that these MCL1-targeting miRNAs suppress MCL1 expression, thereby inducing apoptosis, repressing cancer progression and development, and increasing drug sensitivity in different types of cancers such as lymphoma, osteosarcoma, hepatocellular carcinoma, triple negative breast cancer, endometrial cancer, and cervical cancer, etc20–26.